0001104659-15-051912.txt : 20150720 0001104659-15-051912.hdr.sgml : 20150720 20150720164149 ACCESSION NUMBER: 0001104659-15-051912 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20150720 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150720 DATE AS OF CHANGE: 20150720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 15996181 BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 a15-15956_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 20, 2015

 

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of
Incorporation)

 

001-35518

 

20-2590184

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

1550 East Gude Drive, Rockville MD

 

20850

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (301) 838-2500

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 2.02              Other Events

 

On July 20, 2015, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report financial results for the second quarter ending June 30, 2015 after 5:00 PM ET on August 4, 2015, and will hold a conference call and webcast on August 5, 2015 to review the second quarter 2015 financial results.  A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01              Financial Statements and Exhibits.

 

(d)           Exhibit

 

The following document is furnished as an Exhibit pursuant to Item 2.02 hereof:

 

Exhibit 99.1 — Press Release Dated July 20, 2015.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SUPERNUS PHARMACEUTICALS, INC.

 

 

DATED: July 20, 2015

By:

/s/ Gregory S. Patrick

 

 

Gregory S. Patrick

 

 

Vice-President and Chief Financial Officer

 

3


 

EXHIBIT INDEX

 

Number

 

Description

 

 

 

 

 

 

 

99.1

 

Press Release Dated July 20, 2015.

 

Attached

 

4

 EX-99.1 2 a15-15956_1ex99d1.htm EX-99.1

Exhibit 99.1

 

GRAPHIC

 

Supernus to Host Second Quarter 2015 Earnings Conference Call

 

Rockville, MD, July 20, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the second quarter of 2015 after 5:00 PM ET on Tuesday, August 4, 2015.

 

Jack Khattar, President and Chief Executive Officer and Greg Patrick, Chief Financial Officer, will host a conference call to present the second quarter 2015 results on Wednesday, August 5, 2015 at 9:00 AM ET. Following the presentation, the call will be open for questions.

 

A live webcast will be available at www.supernus.com. Following the live call, a replay will be available on the Company’s website under the ‘Investors’ section. The webcast will be available on the Company’s website for 60 days following the live call.

 

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

 

Conference dial-in:

(877) 288-1043

International dial-in:

(970) 315-0267

Conference ID:

84774084

Conference Call Name:

Supernus Pharmaceuticals 2Q 2015 Earnings Conference Call

 

About Supernus Pharmaceuticals, Inc.

 

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment and SPN-812 for ADHD.

 

CONTACTS:

 

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

 

or

 

INVESTOR CONTACT:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

 

 GRAPHIC 3 g159561mmi001.gif GRAPHIC begin 644 g159561mmi001.gif M1TE&.#EA&@%!`/<``%9BF18J==[C:,G*WLG+WM[C:9&7O%9BFN3D[B@X?_+Q M]]?7YLG*W9&6O'1]JSA&B(.*LZRPS)"6NQ8I=?+P]D94D"@Y?ZVQS=+9:IZD MQ:^X;V5OHDU;=/C[O/SR?[[]B8W=IZCQ/GXY*^X;F9R#E+F?>#F<^GLFUIG7IB(N5 M<.7IA_W[]NONI/?VVN;KD>'F=.?KD?3TRC1#=?_\__[\]S1#=KN^UF5PH_;V MTO7UTG5]J^OMH_KYY')]@<.+G?6=ROMI.GK MF^/G??S[[:2L<%IH=/+SP*BMN^KMHXN6<>_PMZRQS=/9:[S!IX^9A,C,I_3T MT?[\]G>"A;S#;.?KDN7GP;B_E>CKF_?VV]_D:=[D:?_^_Q]0",`-D+Q@&`-%-0!519L^%""1ZDE M4&!%A3C0B(65N%`'@_$"(D<&`*8"!0]I1`8#$D0`'4F7U%""BT^"RF7HH+D(@$%C$SC9 M"P.#??B109`:YBA)'2(%14D--"9<+U4&5L%K"Q%@H*-L$71@2$B@P:::"XV[()"+@7(\I>?+R```/'`:!+A)$ M&<`5!C@0PY)4%=;`IP/!1U0%6"XTA06[#!5IJWUI<9`"#AP60`#MBB2!8`;, M*M`)51[&2[LL];*$@44%,`0`,`0&`:@/\WO%R[U(T%P%F@W$@`5'D=!5$FB, M*5>BN#P8KD\^.%&4#%&,HH$+@KJ@01`[T,"+$#5@\.N@<@6+"Q(WU5336;U` M*9Z38P\$`2\J(!!"!1]B&<,NKJ5-]E=XWVW0`KR(_^"5W10$,*54O7XE$Q)H M#-UUT8(66M^#AW(]=*(%/&A'$FN!E9;>`[4P@&<#4%;9Z*$/<$*6#$AYT,:A M'2EK+Q<$PK,$`P7PNJE;"70`+P/]2+M`"&10P0B\8`1``)-6.8!'&__>BVX< M[N+\5"!NP$OK!EVP@6H=)[2;0!1!+QZT'U7[[7MD^_&/+!I10`\.XP`A%:QANPA+VNAWP,V, MC7`$S-O_,HB^\Z'%@P(Q1!F`-2>K&2A@C>D+4NS$"R?0PH$""151@@1##FH0 MA&'#&_]`LC]WV?`J%B2@W?_.,+G&F:`&0?B#!GBA!!L8!0Y_,(S#(J4@%!:F M12W$!1@*L@#5M,I.0_@`#!MR`>:,[X8Q(,RE%E"<"_'"/`0Y001:AI3FB%%( M%3!*$K$%02&K:.E*EPV4@,))`FPPF^PC MD\YH(D*69&Y'Z1&HD(2=PI5*0:\+R)`+#+Q`3;BHP2Y>8`-<8&`-A,D!"C1`48I2S03$3,I0 M3#`H/QEE!7WBVEP"VCA M0H$9T*PA`R"2E"XX$`RQBBH(89(>'U)&(FT2!@]XR!"H@:71Z$ M`1J\@`IT<0$(!B.#'01!/QIH@@9N@`(BO*`H(,#`#W@!`F>F*U!,6$L%VU*6 M6A4EG9R;H$E2E9*]UO!N`?3A#3,W*3#0Q5K.[.AC0]K1N(@IH/_,+*(^44#& M&O8JJ9MI5T;D)'LVL%,?L)Z43@>\G`+@4[D"0`2,,H!$_TH@#/7B10-:@`.C MO'8F`VC9+OZ5E@CT``J\L,`%%`*!&27@91>`@FQ[00`'T*@7"]C1O`#0@AC, MBR1`4`$`$O!I'3O!'F45PAVQUT$J&876L@`'4%DAMT1Q0$* MT$4>R7,!G@%@`4,VS0,L0*\#$,R&+Q&L8D-"@31"L@(.D(`#AHS-'4JP@X<5 M"P\]MA(@PG.Q9@[S?-/\LSN4`O\+=I""%/"`!R]@01`1FO*&./*CHV!O(3O* MF?STG-@.$K5^C(V)E_FJEE21#8-K%L@@RH`L0O%`"!=SXWA$%A@.5*(.#PE! M879A@"A_%M%C#NQ&#,AH1.OYRQDL&8&[@@3[S,4&+V`0;32-3\'H!9*\H$$A M1%1,7B3@R0+\H/XX>&HHC_'58([T6,@@`17(RSTJB4-E"75$%.1`$;L``5]2 M`*"'0:S7@3DA@4`@!LP1I`>%T0N1AN"S('YD"DL80A4W]1$$Q+AA4W14!V!@ MH`2]MHV<)DQ14HJ0%!?E`2%0J8IW48'3:20"]9HG=KUX0@#HPF`,0MX'>*;N M*FYR"AG_F#AS`(N`&:B;.=FD@+6-7>_6AC.&#M#%B9Y'NPB\CM(DQ`4(?FF$ M)A!A%SH()B]R<2D3MFKAF1EU#!ATFQ&D%3`H$U$GA12`P8C2GOW M8@05:$@&+%!5"O2@\%P85BP!E(L:J&D-NUC!%Y)B@R2>#D$4(+Y*`D#KAG,(_QB`M6T4R,!/ MNV!!+NK$`UQ`E`:X8,&V&I-I76L:8AJ82QK.($O)AK0^_J%Q)"%/S2%V!*%4 MM@-XEC)HQR%#O)`[!^`PO%!SBI5JJ3,4"5@_*#$52*)F1@5/0148!GA-%V-[ MN*(;O^9&X*<67O`KA/)/,@`"+M` M,YL!?%-"*J.VAC5T(0B1%:3'"R.`)1R!`+KBA@6A&R.`;`2Q(T;!*Z_!!2+5 M-8LS%VK01(&"`8YH`G(B%RZP`AR0)\W!`7/``^=(!',U!DPX*&>`'$N`8?&2 M%&_P9V:A`!!P0@D"`P9`,!MC%#T``1'0`@6A5+M@`=0X147Q7/)50QI!`0;` M,%;D'AYQ`3AR(P=@(QQ9(P8!`#AP(QPYDMK)FTEL8I;>&:I MXW$"T8^\425GF6QJ!D^%)38WL0`4N&B]<'UQ29D;L0=;TR=&TW]#Z8*"65*$ M$DNXL`7NQH"HUD-A$0$5H05WH@+601',-V:DY7.-*< MNY,0J>."E2 M!3`+ANF5:-EJYG1`):,0I,405>(=1V(:WIE2D").\>DH(^(\$?@_S6DRO'!' M5>(:%4.*`[$`LQ55`Z$A)4!JZ!%!C\(+TR,I6<`+15!54[``/!D]#=`0WS,` M2R`0?+.8'`0&6'`*-O M@W$`.&EUQO9\KL=HZJ(8P+(2R"C1`!#D`K;QPC+1110$3 M)4XP;`5!`0MR,!3_<&C;RF8+X"][F04\\[*Y`@$O;J0"0Y8`-`(W]=<8$L,9/$-QTD@!JC$4,Z!2 M*30^9-"[&,(;[DM,5@8#2[``"E%=YO:U`E%31&&`%!`!-45ZV=1)"6*I!5%& M<5A\4[@!4:4+#.`H2&!7FW@#O.`"1!`%-<`+1-"VO(`!H+=K*`1U4)<"!:`' M>[,C1N@8@G.U\72,E^(1D-(D)=.,(\#!!@&H2/$`_&0`*=.*=:@@MZH1%8-/ MJO%;O<"/%I``SJ,0M-@85.P1_6@K(-$AA'L0M#?!'>&^6E%#\E0BHC@`&T," M'[`+\%%SF#`T:XL+)K`";((!Y_@#5I`@!3`>?_^[(*&'MSN`"SS\%;D1+PL2 MM3HS:B.8$!WB,'`YA<,)895GZ-31N4+O34RM&D3_G M/%3B.A6TP:M*0HR`]\D(P0`2F"(GP5P-2R`P\-,=00D'^X++O'2Y$,BX@`+A MA@MQS0LZ0"QYH;"CAD_8[++"$@J;V"?_AU_U(!S0O8FCYQMWM,P"ZD7#&QLL'T8)W M_]DXB4Q0/+`+U`(GO`2.0Q$$BC)6H_9R:JH@M01,O*!^(\6)!]LG"$+%>L?7 M-)&%O)#.!T@5!P"P,*0K5J$08:`GW(T_7@?O> M+-`G2\11O)D1WQ&/.2@M)%-H34;K_,2TCD4*OH_-S9#4SU: M%]X2C/W<\38K=ZW<'G.!=5T6W^D0D$T5=(@06'"7R!*4!9`#.2`7);X"`0K+7PWJLUQY-I!HQRPS(V!Y!@(.1T`21X.W\C+P@A1VA MN^?3!HZCYG/!`>>'"XX@`T:`XK9$32\0!(J8"SZ`"#O@E!RP!E$P!BR@`RP= M,"@`38-RCD:1B3UN-`&E2X$A,0=!C8,Q`]ACI@?3!1.0:=D$AT8Q21N8$`HP M9!4WN6C*(`A&`$KF@`<^RUZI=&"``(#(P M!^D738-B"FZ4`B"@`SH0!33_H$GG45@2?,,/L)T+C\U$$;M,8K?&Y@!K%$% M*0$&@&&[D`#UENYGQ@1#6?$I[5`R<.+I(MJ[(`0_X`*+MP-;-31Q0)8#P+72A0,0(`'8<3\(T``B@`-"?^:Z$`(0$`*EB(7Q M-N`+D`4Q0",08`""]C=&\@$&(`(T8@`1@+1Q2:M8"Q8(L/H`D&422A":S_DA MT;008"-"S_N';1.1]]UV56D8<(A1X`B_\@4[@%'\[+)\@`(^\`B#>)0O.#1R M`!,=_TNNPEJ9;?PA^VIJ`?NQ9/J97D;@?*7V`Y'F;P_M:OX%X&8"/_`%T32: MZ>(#**`$+U`#A=(X`)&K0*Y%7#"+J:N@08L.4&5TN9/GR8$,$%B#(5*CBHL*6,W&FW),+%RZ! MN000'$H0Z5!<&)Z`$,(KP"ZI`7CMHK&#QT""`H@J)8I+3T^<91^2A:FP0\6* M&!&B[16SX8"=O2@\X"5!EP%>`S*FA/NS96"S;U7&;4$AKO-S&+>Q3814Q M2HLF%:K4:]*PG(T*92JT0-BCF1=)CHRZ\.#`=-D^7KF0+O_&A@UV'=`E89=) MB80-IX;L$F7L7@I&&!B^^JWCLG`#(['\-313Z0*.XO)Z?:EERT>W)$E-.#GP MWP<_[*+*ZP%/XKT(W#ZX($&"([T,[$H@X<.,70Y$)@""`!5X,2`N''A)X($A M>"%`!`0=&"`#JQZX@(`*>,GBH#=4Z&"D``B(*X893NBEA2(.Z.4*&!3H)0-> M2NBE"P+M(B$!7MQS@)<#2C``@0V8Z^6"!!:P*P$+>JGQ@P'XDP`A'0\JXJ9> M``BA/?8@VL.K@<+:;LNCN,(,K*X*`!,7. MW@,`@0$0:(DOWGIYLA<&6'3O12?_8:.K`83>1&@`7A0]P;`/QBAL5TDT% MCS:ZB2]%#V*TEP$":-))%+/8I86%""#4T1)2JHL1Q_Y4S4J(F-@BNLZXS.PK MS;`#BR@QN%BS6&/?BHFQA!@(`+:4)&`0,B`C*,(!/7!2JNX#$^.99/C8@.+`$'%%.++KUY.>'(V M!1#H@9<-5`7T,5T<]0_4`%KEI5->_`7$@ETB6``!&Q/HH@$`5+C+L0X^`."F M$`)X`($%EP"P\2!'9U`@`@008,XX!"%H8(,>@'!LY0$W(#)F08=0C`)>:O:8 M)S^02(.[7B]&*A%)F#C)8;\[MM4LL@+K:;"?'B+`9*G+*TR!`8[`%X&$%AA4 M(08((/&M`4R&^2#')8^+K`7V#&[S@Q9_:/2TUVPX(P\\Z.7UUWOIHP_886?< 9<,E:;U,XP5H?_..X>0=